<DOC>
	<DOCNO>NCT03073213</DOCNO>
	<brief_summary>The purpose study research much ixekizumab enters bloodstream long body take get rid drug safety ixekizumab side effect might associate . The study two part : A single-dose part multiple-dose part . The single dose part study last 24 week , include screening period . The multiple dose part study last 32 week include screening period .</brief_summary>
	<brief_title>A Study Ixekizumab Chinese Participants With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female participant chronic plaque psoriasis ( great equal 10 percent ( % ) body surface area ( BSA ) ; static Physician 's Global Assessment ( sPGA ) score great equal 3 Psoriasis Area Severity Index ( PASI ) score great equal 12 ) least 6 month baseline Have body mass index 18 35 kilogram per meter square ( kg/mÂ² ) Previously complete withdrawn ixekizumab study study investigate interleukin17 ( IL17 ) antagonist Have active recent infection compromise immune system Have active dormant tuberculosis Have serious unstable/uncontrolled illness , include heart disease , abnormal blood pressure , mental disorder , malignancy disease Be pregnant breastfeeding Had major surgery within 8 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>